Structure Therapeutics (NASDAQ:GPCR) Stock Bumped Down to Strong Sell by Wall Street Zen

Wall Street Zen cut shares of Structure Therapeutics (NASDAQ:GPCR) from a sell rating to a strong sell rating in a report published on Saturday morning,Wall Street Zen reports.

Other analysts have also recently issued research reports about the company. Citizens Jmp reaffirmed a “market outperform” rating and issued a $110.00 price target on shares of Structure Therapeutics in a report on Wednesday, September 9th. Weiss Ratings downgraded shares of Structure Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday, September 18th. Canaccord Genuity Group set a $111.00 target price on shares of Structure Therapeutics in a research report on Friday, August 7th. HC Wainwright reissued a “buy” rating on shares of Structure Therapeutics in a research note on Wednesday, September 9th. Finally, Citigroup reissued a “market outperform” rating on shares of Structure Therapeutics in a report on Friday, August 7th. Two research analysts have rated the stock with a Strong Buy rating, twelve have given a Buy rating, one has issued a Hold rating and two have issued a Sell rating to the company. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $110.91.

Structure Therapeutics Stock Performance

Structure Therapeutics stock opened at $27.67 on Friday. Structure Therapeutics has a fifty-two week low of $25.59 and a fifty-two week high of $94.90. The stock has a market cap of $1.93 billion, a P/E ratio of -27.67 and a beta of -1.30. The firm’s fifty day moving average price is $44.67 and its 200-day moving average price is $45.79.

Structure Therapeutics (NASDAQ:GPCR) last posted its quarterly earnings data on Thursday, August 6th. The company reported ($0.49) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.39) by ($0.10). Sell-side analysts predict that Structure Therapeutics will post -1.87 earnings per share for the current year.

Hedge Funds Weigh In On Structure Therapeutics

Large investors have recently modified their holdings of the company. IFP Advisors Inc purchased a new stake in Structure Therapeutics in the second quarter worth approximately $46,000. Squarepoint Ops LLC lifted its holdings in shares of Structure Therapeutics by 454.5% in the 2nd quarter. Squarepoint Ops LLC now owns 125,575 shares of the company’s stock worth $6,740,000 after acquiring an additional 102,929 shares during the last quarter. Seven Fleet Capital Management LP lifted its holdings in shares of Structure Therapeutics by 197.8% in the 2nd quarter. Seven Fleet Capital Management LP now owns 26,800 shares of the company’s stock worth $1,442,000 after acquiring an additional 17,800 shares during the last quarter. Wellington Management Group LLP lifted its holdings in shares of Structure Therapeutics by 1.6% in the 2nd quarter. Wellington Management Group LLP now owns 7,379,433 shares of the company’s stock worth $396,054,000 after acquiring an additional 119,146 shares during the last quarter. Finally, Handelsbanken Fonder AB purchased a new stake in shares of Structure Therapeutics in the 2nd quarter valued at $1,041,000. 91.78% of the stock is owned by hedge funds and other institutional investors.

About Structure Therapeutics

Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing oral small-molecule medicines for chronic metabolic and cardiopulmonary diseases. The company uses structure-based drug discovery and related technologies to identify therapies intended to address conditions with significant unmet medical needs.

Its lead product candidate is GSBR-1290, an investigational oral small-molecule agonist of the glucagon-like peptide-1 (GLP-1) receptor being developed for obesity and type 2 diabetes.